Hocher B, George I, Rebstock J, Bauch A, Schwarz A, Neumayer H H, Bauer C
Department of Nephrology, Universitätsklinikum Charité der Humboldt Universität zu Berlin, Germany.
Hypertension. 1999 Mar;33(3):816-22. doi: 10.1161/01.hyp.33.3.816.
The aim of the present study was to analyze whether the cardiac endothelin system contributes to cardiac remodeling in rats with 2-kidney, 1 clip (2K1C) renovascular hypertension. The endothelin system seems to be a promising candidate for cardiac remodeling because endothelin (ET)-1 promotes growth of cardiomyocytes in vitro and induces cardiac collagen synthesis. The activity of the cardiac endothelin system was analyzed by measuring cardiac tissue big ET-1 and ET-1 concentrations as well as by estimating the cardiac expression of the ETA and ETB receptors 10 days, 4 weeks, and 12 weeks after the renal artery was clipped. The effects of long-term treatment with ETA, ETB, and combined ETA/ETB receptor antagonists on cardiac hypertrophy, media/lumen ratio of intracardiac arteries, and left ventricular fibrosis were also analyzed. This study demonstrated that the overall left ventricular cardiac endothelin system has a similar activity in the early, middle, and late stages of 2K1C renovascular hypertension compared with sham-operated controls. Fibrosis of the left ventricle and hypertrophy of intracardiac arteries, however, were markedly altered after long-term treatment with endothelin receptor antagonists in a blood pressure-independent manner. These 2 effects are mediated by different subtypes of endothelin receptors. ETA receptor blockade completely normalized the hypertrophy of intracardiac arteries (P<0. 01 compared with 2K1C without treatment) in renovascular hypertension, whereas the ETB antagonist reduced cardiac fibrosis of the left ventricle (P<0.001 compared with 2K1C without treatment) to baseline values. This study demonstrates that the cardiac endothelin system plays an important role in the development of cardiac fibrosis as well as in hypertrophy of intracardiac arteries in 2K1C renovascular hypertensive rats.
本研究的目的是分析心脏内皮素系统是否参与两肾一夹(2K1C)肾血管性高血压大鼠的心脏重塑。内皮素系统似乎是心脏重塑的一个有前景的候选因素,因为内皮素(ET)-1在体外可促进心肌细胞生长并诱导心脏胶原蛋白合成。在肾动脉夹闭后10天、4周和12周,通过测量心脏组织中大分子ET-1和ET-1浓度以及评估ETA和ETB受体的心脏表达,来分析心脏内皮素系统的活性。还分析了长期使用ETA、ETB以及ETA/ETB受体拮抗剂联合治疗对心脏肥大、心脏内动脉中膜/管腔比值和左心室纤维化的影响。本研究表明,与假手术对照组相比,在2K1C肾血管性高血压的早期、中期和晚期,整体左心室心脏内皮素系统具有相似的活性。然而,在用内皮素受体拮抗剂长期治疗后,左心室纤维化和心脏内动脉肥大以血压非依赖性方式发生了显著改变。这两种效应由不同亚型的内皮素受体介导。在肾血管性高血压中,ETA受体阻断可使心脏内动脉肥大完全恢复正常(与未治疗的2K1C相比,P<0.01),而ETB拮抗剂可将左心室心脏纤维化(与未治疗的2K1C相比,P<0.001)降低至基线值。本研究表明,心脏内皮素系统在2K1C肾血管性高血压大鼠的心脏纤维化发展以及心脏内动脉肥大过程中起重要作用。